In the past week, TLSI stock has gone down by -26.14%, with a monthly decline of -26.74% and a quarterly plunge of -20.49%. The volatility ratio for the week is 4.74%, and the volatility levels for the last 30 days are 4.87% for TriSalus Life Sciences Inc The simple moving average for the last 20 days is -24.84% for TLSI stock, with a simple moving average of -4.80% for the last 200 days.
Is It Worth Investing in TriSalus Life Sciences Inc (NASDAQ: TLSI) Right Now?
Additionally, the 36-month beta value for TLSI is 0.66. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for TLSI is 2.73M and currently, short sellers hold a 6.21% ratio of that float. The average trading volume of TLSI on May 24, 2024 was 40.60K shares.
TLSI) stock’s latest price update
The stock of TriSalus Life Sciences Inc (NASDAQ: TLSI) has decreased by -23.74 when compared to last closing price of 9.54. Despite this, the company has experienced a -26.14% fall in its stock price over the last five trading sessions. businesswire.com reported 2024-05-24 that DENVER–(BUSINESS WIRE)–TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today that it has commenced an exchange offer (the “Offer”) and consent solicitation (the “Consent Solicitation”) relating to its warrants (the “Warrants”) identified in the Prospectus/Offer to Exchange (as defined below). The purpose of.
TLSI Trading at -24.86% from the 50-Day Moving Average
After a stumble in the market that brought TLSI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.20% of loss for the given period.
Volatility was left at 4.87%, however, over the last 30 days, the volatility rate increased by 4.74%, as shares sank -23.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.63% lower at present.
During the last 5 trading sessions, TLSI fell by -27.82%, which changed the moving average for the period of 200-days by -25.60% in comparison to the 20-day moving average, which settled at $9.57. In addition, TriSalus Life Sciences Inc saw -13.91% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for TLSI
Current profitability levels for the company are sitting at:
- -2.53 for the present operating margin
- 0.87 for the gross margin
The net margin for TriSalus Life Sciences Inc stands at -2.91. The total capital return value is set at -15.94. Equity return is now at value -2.48, with -265.61 for asset returns.
Based on TriSalus Life Sciences Inc (TLSI), the company’s capital structure generated -0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -31.88. The debt to equity ratio resting at -0.05. The interest coverage ratio of the stock is -3979.57.
Currently, EBITDA for the company is -53.4 million with net debt to EBITDA at 0.04. When we switch over and look at the enterprise to sales, we see a ratio of 9.16. The receivables turnover for the company is 5.14for trailing twelve months and the total asset turnover is 1.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.92.
Conclusion
In conclusion, TriSalus Life Sciences Inc (TLSI) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
